Breaking News Instant updates and real-time market news.

SCYX

Scynexis

$7.32 /

+0.05 (+0.69%)

08:09
07/12/21
07/12
08:09
07/12/21
08:09

Scynexis announces three oral presentations on ibrexafungerp

SCYNEXIS announced three oral presentations demonstrating the potential clinical utility of ibrexafungerp at the 31st European Congress of Clinical Microbiology and Infectious Diseases. "Fungal infections worldwide are becoming increasingly drug-resistant and more deadly, leaving patients with limited treatment options. However, we believe that ibrexafungerp has the potential to be effective against many drug-resistant fungal pathogens, like Candida auris, which has capitalized on the crowded hospital conditions created by the COVID-19 pandemic," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "These presentations continue to build on the positive responses we've seen in both the CARES and FURI studies and support ibrexafungerp's potential to be the treatment option that patients need. We continue to actively enroll patients in both studies." Presentation titled, "EUCAST Ibrexafungerp MICs for contemporary Danish Yeast Isolates" found an in vitro susceptibility analysis of 967 unique yeast isolates from 794 patients found that ibrexafungerp displayed broad activity. Additional analysis demonstrated that ibrexafungerp was active in most strains harboring mutations in the fks gene, commonly associated with echinocandin resistance. The second presentation is titled, "Outcomes of Oral Ibrexafungerp in 33 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study." In an interim analysis by an independent data review committee of 33 patients from the Phase 3 FURI study evaluating ibrexafungerp for the treatment of patients with refractory fungal disease found that 23 patients achieved clinical improvement, defined as complete or partial response. 7 patients maintained stable disease and 0 patients progressed. 3 patients were considered as indeterminate. Overall, ibrexafungerp was well-tolerated, with the most common treatment-related adverse events being gastrointestinal in nature. The third presentation is titled, "Outcomes of Oral Ibrexafungerp in the Treatment of Ten Patients with Candida auris Infections, from the CARES Study." This reviews an interim analysis by an independent data review committee of 10 patients from the global Phase 3 CARES study evaluating ibrexafungerp for the treatment of patients with invasive candidiasis or candidemia due to Candida auris found that 8 patients had a complete response. One patient was considered indeterminate, and one patient died of other causes.

  • 13

    Jul

  • 17

    Dec

SCYX Scynexis
$7.32 /

+0.05 (+0.69%)

02/17/21 Maxim
Scynexis price target raised to $22 from $17 at Maxim
01/22/21 Guggenheim
Scynexis initiated with a Buy at Guggenheim
01/05/21 Cantor Fitzgerald
Scynexis initiated with an Overweight at Cantor Fitzgerald
12/28/20 H.C. Wainwright
Scynexis price target lowered to $20 from $35 at H.C. Wainwright

TODAY'S FREE FLY STORIES

Downgrade
SolarEdge downgraded to Neutral from Buy at Guggenheim » 05:33
10/20/21
10/20
05:33
10/20/21
05:33
SEDG

SolarEdge

$317.26 /

+11.51 (+3.76%)

Guggenheim analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SEDG SolarEdge
$317.26 /

+11.51 (+3.76%)

SEDG SolarEdge
$317.26 /

+11.51 (+3.76%)

09/30/21 BMO Capital
SolarEdge initiated with an Outperform at BMO Capital
08/31/21 Wolfe Research
SolarEdge initiated with an Outperform at Wolfe Research
08/24/21 GLJ Research
California data 'increasingly troubling' for SolarEdge, Enphase, says GLJ
08/13/21 GLJ Research
JinkoSolar shipment into U.S. stopped by customs, says GLJ Research
SEDG SolarEdge
$317.26 /

+11.51 (+3.76%)

SEDG SolarEdge
$317.26 /

+11.51 (+3.76%)

SEDG SolarEdge
$317.26 /

+11.51 (+3.76%)

Upgrade
W&T Offshore upgraded to Buy from Hold at Stifel » 05:33
10/20/21
10/20
05:33
10/20/21
05:33
WTI

W&T Offshore

$4.06 /

-0.11 (-2.64%)

Stifel analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WTI W&T Offshore
$4.06 /

-0.11 (-2.64%)

WTI W&T Offshore
$4.06 /

-0.11 (-2.64%)

09/09/21 Roth Capital
W&T Offshore should be bought on any weakness, says Roth Capital
11/05/20 Capital One
W&T Offshore upgraded to Equalweight from Underweight at Capital One
WTI W&T Offshore
$4.06 /

-0.11 (-2.64%)

WTI W&T Offshore
$4.06 /

-0.11 (-2.64%)

WTI W&T Offshore
$4.06 /

-0.11 (-2.64%)

Downgrade
IAG downgraded to Hold from Buy at Peel Hunt » 05:31
10/20/21
10/20
05:31
10/20/21
05:31
ICAGY

IAG

$4.56 /

-0.2299 (-4.80%)

Peel Hunt analyst Alex…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ICAGY IAG
$4.56 /

-0.2299 (-4.80%)

10/19/21 Berenberg
IAG downgraded to Hold from Buy at Berenberg
10/13/21 Barclays
IAG price target lowered to 215 GBp from 230 GBp at Barclays
10/11/21 UBS
IAG price target lowered to 245 GBp from 255 GBp at UBS
09/29/21 Deutsche Bank
IAG upgraded to Buy from Hold at Deutsche Bank
Upgrade
Moneysupermarket.com upgraded to Buy from Hold at Berenberg » 05:29
10/20/21
10/20
05:29
10/20/21
05:29
MYSRF

Moneysupermarket.com

$2.57 /

+ (+0.00%)

Berenberg analyst Edward…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MYSRF Moneysupermarket.com
$2.57 /

+ (+0.00%)

10/05/21 Credit Suisse
Moneysupermarket.com price target lowered to 250 GBp at Credit Suisse
09/22/21 Barclays
Moneysupermarket.com price target lowered to 275 GBp from 310 GBp at Barclays
Downgrade
Maersk Drilling downgraded to Hold from Buy at Pareto » 05:27
10/20/21
10/20
05:27
10/20/21
05:27
DDRLF

Maersk Drilling

$38.92 /

+ (+0.00%)

Pareto analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DDRLF Maersk Drilling
$38.92 /

+ (+0.00%)

10/15/21 JPMorgan
Maersk Drilling price target raised to DKK 285 from DKK 284 at JPMorgan
10/15/21 SEB Equities
Maersk Drilling upgraded to Buy from Hold at SEB Equities
08/23/21 Kepler Cheuvreux
Maersk Drilling upgraded to Hold from Reduce at Kepler Cheuvreux
08/23/21 DNB Markets
Maersk Drilling upgraded to Buy from Hold at DNB Markets
Hot Stocks
FinVolution Group sees FY21 transaction volume RMB 130B-RMB 135B » 05:27
10/20/21
10/20
05:27
10/20/21
05:27
FINV

FinVolution Group

$5.95 /

+0.125 (+2.15%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FINV FinVolution Group
$5.95 /

+0.125 (+2.15%)

FINV FinVolution Group
$5.95 /

+0.125 (+2.15%)

09/21/21
Fly Intel: Top five analyst initiations
09/21/21 China Renaissance
FinVolution initiated with Buy, $9.20 target at China Renaissance
09/21/21 China Renaissance
FinVolution Group initiated with a Buy at China Renaissance
08/24/21 Citi
FinVolution Group downgraded to Neutral from Buy at Citi
FINV FinVolution Group
$5.95 /

+0.125 (+2.15%)

Upgrade
New Work upgraded to Buy from Hold at Pareto » 05:25
10/20/21
10/20
05:25
10/20/21
05:25
XINXF

New Work

$300.94 /

+ (+0.00%)

Pareto analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Downgrade
Entra downgraded to Hold from Buy at DNB Markets » 05:24
10/20/21
10/20
05:24
10/20/21
05:24
ENTOF

Entra

$22.10 /

+ (+0.00%)

DNB Markets analyst Simen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ENTOF Entra
$22.10 /

+ (+0.00%)

10/13/21 DNB Markets
Entra upgraded to Buy from Hold at DNB Markets
02/09/21 Barclays
Entra downgraded to Equal Weight from Overweight at Barclays
01/13/21 Kepler Cheuvreux
Entra downgraded to Hold from Buy at Kepler Cheuvreux
10/22/20 Barclays
Entra upgraded to Overweight from Underweight at Barclays
Earnings
ASML reports Q3 EPS EUR 4.27 vs. EUR 2.52 last year » 05:24
10/20/21
10/20
05:24
10/20/21
05:24
ASML

ASML

$800.81 /

+12.73 (+1.62%)

Reports Q3 revenue EUR…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASML ASML
$800.81 /

+12.73 (+1.62%)

ASML ASML
$800.81 /

+12.73 (+1.62%)

10/14/21 Piper Sandler
Piper Sandler starts ASML at Overweight amid 'powerful tailwinds'
10/14/21 Piper Sandler
ASML initiated with an Overweight at Piper Sandler
09/28/21 New Street
ASML downgraded to Neutral from Buy at New Street
09/24/21 Morgan Stanley
ASML price target raised to EUR 800 from EUR 720 at Morgan Stanley
ASML ASML
$800.81 /

+12.73 (+1.62%)

ASML ASML
$800.81 /

+12.73 (+1.62%)

ASML ASML
$800.81 /

+12.73 (+1.62%)

ASML ASML
$800.81 /

+12.73 (+1.62%)

Upgrade
Norway Royal Salmon upgraded to Buy from Hold at DNB Markets » 05:24
10/20/21
10/20
05:24
10/20/21
05:24
NRYYF

Norway Royal Salmon

$24.25 /

+ (+0.00%)

DNB Markets analyst Stein…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NRYYF Norway Royal Salmon
$24.25 /

+ (+0.00%)

05:23 Today Kepler Cheuvreux
Norway Royal Salmon upgraded to Buy from Hold at Kepler Cheuvreux
08/24/21 DNB Markets
Norway Royal Salmon downgraded to Hold from Buy at DNB Markets
02/02/21 Fearnley
Norway Royal Salmon upgraded to Buy from Hold at Fearnley
01/18/21 Danske Bank
Norway Royal Salmon upgraded to Buy from Hold at Danske Bank
Upgrade
Norway Royal Salmon upgraded to Buy from Hold at Kepler Cheuvreux » 05:23
10/20/21
10/20
05:23
10/20/21
05:23
NRYYF

Norway Royal Salmon

$24.25 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NRYYF Norway Royal Salmon
$24.25 /

+ (+0.00%)

08/24/21 DNB Markets
Norway Royal Salmon downgraded to Hold from Buy at DNB Markets
02/02/21 Fearnley
Norway Royal Salmon upgraded to Buy from Hold at Fearnley
01/18/21 Danske Bank
Norway Royal Salmon upgraded to Buy from Hold at Danske Bank
Upgrade
Bakkafrost upgraded to Buy from Hold at Kepler Cheuvreux » 05:22
10/20/21
10/20
05:22
10/20/21
05:22
BKFKF

Bakkafrost

$85.78 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BKFKF Bakkafrost
$85.78 /

+ (+0.00%)

04/13/21 Pareto
Bakkafrost upgraded to Hold from Sell at Pareto
11/11/20 Danske Bank
Bakkafrost downgraded to Hold from Buy at Danske Bank
Upgrade
Salmones Camanchaca upgraded to Buy from Hold at Kepler Cheuvreux » 05:22
10/20/21
10/20
05:22
10/20/21
05:22
SLMCF

Salmones Camanchaca

$5.50 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Rocket Pharmaceuticals announces interim data from RP-L201 trial at ESGCT » 05:19
10/20/21
10/20
05:19
10/20/21
05:19
RCKT

Rocket Pharmaceuticals

$28.06 /

+0.49 (+1.78%)

Rocket Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$28.06 /

+0.49 (+1.78%)

RCKT Rocket Pharmaceuticals
$28.06 /

+0.49 (+1.78%)

10/19/21 Cowen
Rocket Pharmaceuticals assumed with an Outperform at Cowen
04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
RCKT Rocket Pharmaceuticals
$28.06 /

+0.49 (+1.78%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$28.06 /

+0.49 (+1.78%)

Hot Stocks
Alibaba kicks off 11.11 Global Shopping Festival » 05:15
10/20/21
10/20
05:15
10/20/21
05:15
BABA

Alibaba

$177.02 /

+10.22 (+6.13%)

Alibaba officially kicked…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BABA Alibaba
$177.02 /

+10.22 (+6.13%)

BABA Alibaba
$177.02 /

+10.22 (+6.13%)

10/01/21
Fly Intel: Top five analyst downgrades
10/01/21 KeyBanc
Alibaba price target lowered to $200 from $250 at KeyBanc
10/01/21 Raymond James
Alibaba downgraded to Outperform from Strong Buy at Raymond James
10/01/21 Raymond James
Alibaba downgraded to Outperform from Strong Buy at Raymond James
BABA Alibaba
$177.02 /

+10.22 (+6.13%)

BABA Alibaba
$177.02 /

+10.22 (+6.13%)

BABA Alibaba
$177.02 /

+10.22 (+6.13%)

BABA Alibaba
$177.02 /

+10.22 (+6.13%)

General news
FX Action: The yen posted fresh trend lows » 05:15
10/20/21
10/20
05:15
10/20/21
05:15
$ECON

Economic Data

/

+

FX Action: The yen posted…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Hot Stocks
Triumph Group, Air France-KLM finalize formation of xCelle Americas JV » 05:12
10/20/21
10/20
05:12
10/20/21
05:12
TGI

Triumph Group

$19.77 /

-0.11 (-0.55%)

, AFLYY

Air France-KLM

$4.70 /

-0.155 (-3.20%)

Triumph Group (TGI) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TGI Triumph Group
$19.77 /

-0.11 (-0.55%)

AFLYY Air France-KLM
$4.70 /

-0.155 (-3.20%)

TGI Triumph Group
$19.77 /

-0.11 (-0.55%)

08/06/21 UBS
Triumph Group upgraded to Buy from Neutral at UBS
08/05/21 Baird
Triumph Group designated a bullish Fresh Pick at Baird
06/18/21 Truist
Triumph Group price target raised to $30 from $21 at Truist
05/21/21 Canaccord
Triumph Group price target raised to $15 from $13 at Canaccord
AFLYY Air France-KLM
$4.70 /

-0.155 (-3.20%)

10/13/21 Barclays
Air France-KLM price target lowered to EUR 4.40 from EUR 5.50 at Barclays
08/03/21 UBS
Air France-KLM price target raised to EUR 4.60 from EUR 4.35 at UBS
08/02/21 Barclays
Air France-KLM price target raised to EUR 5.50 from EUR 5.20 at Barclays
05/10/21 Berenberg
Air France-KLM price target raised to EUR 3.60 from EUR 3 at Berenberg
TGI Triumph Group
$19.77 /

-0.11 (-0.55%)

TGI Triumph Group
$19.77 /

-0.11 (-0.55%)

Hot Stocks
Novavax sinks 15% following Politico report of vaccine production issues  05:11
10/20/21
10/20
05:11
10/20/21
05:11
NVAX

Novavax

$160.50 /

-5.8 (-3.49%)

 
ShowHide Related Items >><<
NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

09/08/21 Cantor Fitzgerald
Novavax combo vaccine could have 'differentiating' value, says Cantor Fitzgerald
08/30/21 B. Riley
Novavax is leader in making Covid-flu combination candidate, says B. Riley
08/04/21 Cantor Fitzgerald
Novavax EU deal suggests bottlenecks have been resolved, says Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

Periodicals
Novavax running into production problems with Covid vaccine, Politico reports » 05:11
10/20/21
10/20
05:11
10/20/21
05:11
NVAX

Novavax

$160.50 /

-5.8 (-3.49%)

Novavax (NVAX) has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

09/08/21 Cantor Fitzgerald
Novavax combo vaccine could have 'differentiating' value, says Cantor Fitzgerald
08/30/21 B. Riley
Novavax is leader in making Covid-flu combination candidate, says B. Riley
08/04/21 Cantor Fitzgerald
Novavax EU deal suggests bottlenecks have been resolved, says Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

NVAX Novavax
$160.50 /

-5.8 (-3.49%)

Earnings
Lithia & Driveway reports Q3 adjusted EPS $11.21, consensus $9.28 » 05:09
10/20/21
10/20
05:09
10/20/21
05:09
LAD

Lithia & Driveway

$338.93 /

+0.745 (+0.22%)

Reports Q3 revenue $6.2B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LAD Lithia & Driveway
$338.93 /

+0.745 (+0.22%)

LAD Lithia & Driveway
$338.93 /

+0.745 (+0.22%)

07/22/21 Craig-Hallum
Lithia Motors price target raised to $520 from $500 at Craig-Hallum
07/16/21 BofA
Lithia Motors price target raised to $467 from $460 at BofA
05/21/21
Fly Intel: Top five analyst upgrades
05/21/21 BofA
Lithia Motors upgraded to Buy at BofA on M&A growth potential
LAD Lithia & Driveway
$338.93 /

+0.745 (+0.22%)

  • 20
    May
LAD Lithia & Driveway
$338.93 /

+0.745 (+0.22%)

Recommendations
Piper Sandler remains constructive on Tactile Systems after recent selloff » 05:04
10/20/21
10/20
05:04
10/20/21
05:04
TCMD

Tactile Systems

$36.11 /

+2 (+5.86%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TCMD Tactile Systems
$36.11 /

+2 (+5.86%)

TCMD Tactile Systems
$36.11 /

+2 (+5.86%)

07/07/21 Piper Sandler
Tactile Systems qui tam lawsuit timeline extended, says Piper Sandler
07/06/21 Piper Sandler
Tactile Systems has 'long runway for growth,' says Piper Sandler
03/30/21 Piper Sandler
Tactile Systems granted partial favorable judgment, says Piper Sandler
02/24/21 Piper Sandler
Tactile Systems valuation attractive despite guidance, says Piper Sandler
TCMD Tactile Systems
$36.11 /

+2 (+5.86%)

Recommendations
Microsoft price target raised to $375 from $345 at Jefferies » 05:01
10/20/21
10/20
05:01
10/20/21
05:01
MSFT

Microsoft

$308.30 /

+0.84 (+0.27%)

Jefferies analyst Brent…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$308.30 /

+0.84 (+0.27%)

MSFT Microsoft
$308.30 /

+0.84 (+0.27%)

10/18/21 Morgan Stanley
Morgan Stanley says Cloud, Hybrid solutions should power 'strong' Microsoft Q1
10/06/21 Morgan Stanley
CIO survey shows Microsoft 'further solidifying leadership,' says Morgan Stanley
09/24/21 Oppenheimer
Opco downgrades Cloudflare amid competition from Amazon, Microsoft
09/24/21 Piper Sandler
Salesforce upgraded to Overweight from Neutral at Piper Sandler
MSFT Microsoft
$308.30 /

+0.84 (+0.27%)

MSFT Microsoft
$308.30 /

+0.84 (+0.27%)

MSFT Microsoft
$308.30 /

+0.84 (+0.27%)

MSFT Microsoft
$308.30 /

+0.84 (+0.27%)

Recommendations
Intuitive Surgical price target raised to $330 from $323 at Piper Sandler » 04:59
10/20/21
10/20
04:59
10/20/21
04:59
ISRG

Intuitive Surgical

$336.63 /

+4.45 (+1.34%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ISRG Intuitive Surgical
$336.63 /

+4.45 (+1.34%)

ISRG Intuitive Surgical
$336.63 /

+4.45 (+1.34%)

10/01/21 Citi
Intuitive Surgical downgraded to Neutral from Buy at Citi
09/10/21 Stifel
Intuitive Surgical CFO commentary suggests negative revenue impact, says Stifel
07/22/21 Deutsche Bank
Intuitive Surgical price target raised to $925 from $825 at Deutsche Bank
07/21/21 SVB Leerink
Intuitive Surgical price target raised to $975 from $930 at SVB Leerink
ISRG Intuitive Surgical
$336.63 /

+4.45 (+1.34%)

ISRG Intuitive Surgical
$336.63 /

+4.45 (+1.34%)

ISRG Intuitive Surgical
$336.63 /

+4.45 (+1.34%)

ISRG Intuitive Surgical
$336.63 /

+4.45 (+1.34%)

Recommendations
Netflix Q4 content slate 'still looks compelling,' says Piper Sandler » 04:58
10/20/21
10/20
04:58
10/20/21
04:58
NFLX

Netflix

$639.47 /

+1.62 (+0.25%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NFLX Netflix
$639.47 /

+1.62 (+0.25%)

NFLX Netflix
$639.47 /

+1.62 (+0.25%)

04:51 Today Pivotal Research
Netflix price target raised to $750 from $700 at Pivotal Research
10/19/21 Truist
Netflix's Q3 results 'very solid', says Truist
10/18/21 Loop Capital
Netflix price target raised to $700 from $650 at Loop Capital
10/18/21 UBS
Netflix price target raised to $720 from $620 at UBS
NFLX Netflix
$639.47 /

+1.62 (+0.25%)

NFLX Netflix
$639.47 /

+1.62 (+0.25%)

NFLX Netflix
$639.47 /

+1.62 (+0.25%)

NFLX Netflix
$639.47 /

+1.62 (+0.25%)

Initiation
Jasper Therapeutics initiated with an Outperform at BMO Capital » 04:55
10/20/21
10/20
04:55
10/20/21
04:55
JSPR

Jasper Therapeutics

$13.40 /

+0.04 (+0.30%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JSPR Jasper Therapeutics
$13.40 /

+0.04 (+0.30%)

JSPR Jasper Therapeutics
$13.40 /

+0.04 (+0.30%)

10/12/21 Oppenheimer
Oppenheimer starts 'emerging leader' Jasper Therapeutics with Outperform
10/12/21 Oppenheimer
Jasper Therapeutics initiated with an Outperform at Oppenheimer
JSPR Jasper Therapeutics
$13.40 /

+0.04 (+0.30%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.